Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Incidental metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma: a case report

  • Zareen Kiran1Email author,
  • Asma Ahmed1,
  • Owais Rashid1,
  • Saira Fatima2,
  • Faizan Malik2,
  • Saulat Fatimi3 and
  • Mubassher Ikram4
Journal of Medical Case Reports201711:81

https://doi.org/10.1186/s13256-017-1234-2

Received: 27 December 2016

Accepted: 8 February 2017

Published: 26 March 2017

Abstract

Background

Atypical carcinoid arising from the mediastinal tissue is a rare neuroendocrine tumor and an association with parathyroid adenoma is very unusual. We report an unusual case of atypical carcinoid of mediastinum with metastasis in a patient presenting with parathyroid adenoma, which is the first case to be reported from Pakistan.

Case presentation

A 51-year-old Pakistani man was seen in postoperative intensive care after right parathyroidectomy and mediastinal mass resection for the management of postoperative hypocalcaemia. He had a background history of dyspnea. Examination was unremarkable. Preoperative laboratory evaluation revealed a calcium level of 12.7 mg/dl, phosphate of 1.9 mg/dl, serum albumin of 4.8 g/dl, alkaline phosphate of 94 U/L, and serum intact parathyroid hormone level 413.8 pg/ml. A technetium-99m sestamibi parathyroid scan showed right parathyroid increased tracer uptake. Further workup revealed a large mediastinal mass which was diagnosed as atypical carcinoid after Tru-Cut biopsy. He underwent right-sided parathyroidectomy and resection of the mediastinal mass. The histopathology confirmed it to be a parathyroid adenoma and atypical carcinoid tumor of his mediastinum with metastasis in his lymph node and parathyroid gland. Somatostatin receptor scintigraphy revealed a well-defined focus in his left hypochondriac region consistent with a somatostatin receptor scintigraphy-avid tumor. He was started on everolimus and planned for octreotide therapy.

Conclusions

We describe an incidental finding of atypical carcinoid of the mediastinum in a patient diagnosed as having parathyroid adenoma. Clinical manifestations of neuroendocrine syndromes are challenging. Some tumors cluster in a non-classic description with other common neoplasms. They rarely present in isolation, remain clinically silent, and need aggressive workup with the aid of imaging and histopathology.

Keywords

Parathyroid neoplasms Atypical carcinoid Multiple endocrine neoplasia Case report

Background

Primary neuroendocrine tumors of the mediastinum are rare. They can arise from thymic or non-thymic tissue, can be low to high grade and classified as well-differentiated or poorly differentiated neoplasms [1]. Among the well-differentiated category, we still find the terms “carcinoid” and “atypical” carcinoid in use in the literature [2, 3]. Atypical thymic carcinoid, a rare type of neuroendocrine tumor, has been described as a separate entity [4] as well as in combination with multiple endocrine neoplasia (MEN) type 1 [5]; however, atypical carcinoid arising in the mediastinum is very rare [1]. Most of the literature on neuroendocrine tumors is described in isolation and no substantial data describe an association with parathyroid adenoma from the South Asian region [6, 7]. We describe an incidentally diagnosed metastatic atypical carcinoid from mediastinal tissue in a patient presenting with parathyroid adenoma, which to the best of our knowledge is the first case reported from Pakistan.

Case presentation

A 51-year-old Pakistani man with diabetes was seen in postoperative care for hypocalcemia following parathyroidectomy of his parathyroid adenoma. He was a non-tobacco smoker, with a history of bilateral pedal edema for 1.5 months, and myalgia and dyspnea for less than 1 month. There was a history of renal stones treated with lithotripsy 7 years earlier. His medications included Mixtard-30 (human insulin), sitagliptin, metformin, and furosemide. His family history was insignificant. On examination he was well oriented and his vital signs were stable. A general physical examination revealed only mild pedal edema. A systemic examination was unremarkable. Preoperative investigations showed a calcium (Ca) level of 12.7 mg/dl, phosphate (PO4) 1.9 mg/dl, and serum albumin of 4.8g/dl; his alkaline phosphate 94 U/L and serum intact parathyroid hormone (PTH) level was 413.8 pg/ml. His serum creatinine was 1.04 mg/dl and he had an estimated glomerular filtration rate (eGFR) of 75.28 ml per minute/1.73m2. An ultrasound of his abdomen showed bilateral medullary nephrocalcinosis. An ultrasound of his neck revealed that his right thyroid lobe was mildly enlarged and both lobes showed a few small scattered solid nodules less than 10 mm. His right inferior parathyroid gland was markedly enlarged measuring 3.9×1.3×2.3 cm. Thyroid function tests were normal. A technetium-99m (99mTc) sestamibi parathyroid scan was carried out, which showed a focal area of intensely increased tracer uptake in his right thyroid lobe, which after washout still showed intense tracer accumulation with a probability of parathyroid adenoma or hyperplasia in the right group of parathyroid glands (Fig. 1). On further workup, a chest X-ray revealed a left-sided mediastinal mass (Fig. 2a). Computed tomography of his chest with contrast showed an anterior mediastinal mass measuring 142 mm in diameter showing calcification (Fig. 2b). He underwent Tru-Cut biopsy of this mass and histopathology revealed fibrocollagenous tissue showing sheets of neoplastic cells. After immunohistochemical staining and based on raised proliferative index (Ki-67 10%), this tumor was classified as atypical carcinoid tumor. He was planned for resection of this tumor as well as parathyroidectomy in a one-stage surgery.
Fig. 1

Technetium-99m sestamibi parathyroid scan. The scan shows focal area of increased uptake in right thyroid lobe

Fig. 2

Radiological findings of mediastinal mass. a Chest X-ray showing large left mediastinal mass. b Computed tomography of chest with contrast showing left-sided radiodense mass with calcifications

He developed hypocalcaemia postoperatively which was adequately treated. His postoperative PTH came down to 45.90 pg/ml. The histopathology of the mediastinal tumor measuring 18×15×14 cm and level 5 mediastinal lymph node measuring 0.5×0.3 cm retrieved during surgery revealed an encapsulated lesion comprising diffuse sheets and nests of neoplastic cells, separated by thick and thin fibrous bands. An occasional mitotic figure was seen: up to 2/10 to 3/10 high-power field (HPF). In some areas the tumor cells formed rosette-like structures. Large areas of necrosis were seen along with extensive homogenous, fibrotic areas (Fig. 3c). These areas were negative for Congo red or Sirius red special stains. An immunohistochemical examination showed the same reactivity pattern as the Tru-Cut biopsy. Histopathology of the parathyroid tissue showed fragmented tissue, without cytological atypia, mitotic activity, perineural invasion, indicating parathyroid adenoma (Fig. 3d). There were clusters of neuroendocrine cells, suggestive of involvement by mediastinal atypical carcinoid. A section from his lymph node was also positive for tumor metastasis. These features were consistent with atypical carcinoid tumor with lymph node metastasis. His urinary 5-hydroxyindoleacetic acid (5-HIAA) was only mildly elevated: 7.9 mg/24 hours (2–7). His serum prolactin level was 5.90 U/L (<23.8). Later, somatostatin receptor scintigraphy (SRS) revealed a well-defined focus in his left hypochondriac region between the inner border of his spleen and his left upper renal pole, consistent with SRS-avid tumor (Fig. 4). Another area of increased tracer uptake was noted involving his right thyroid bed. He has been started on everolimus and planned for octreotide therapy. He is currently asymptomatic and recovering well.
Fig. 3

Histopathology of mediastinal mass and parathyroid tissue. a Immunohistochemical stain positive for chromogranin-A. b Mib-1 (Ki-67) positivity in mediastinal mass. c Hematoxylin and eosin staining of the mediastinal mass showing diffuse sheets and nests of neoplastic cells, separated by thick and thin fibrous bands. d Histologic findings of the parathyroid tissue without cytological atypia or mitotic activity favoring parathyroid adenoma

Fig. 4

Somatostatin receptor imaging with technetium-99m hydrazinonicotinamide octreotide. Somatostatin receptor scintigraphy image revealed a well-defined focus in left hypochondrium consistent with somatostatin receptor scintigraphy-avid tumor. Another area of increased tracer uptake of moderate intensity involved the right thyroid bed

Discussion

Neuroendocrine tumors arising from the thymus itself account for just 2 to 5% of primary thymic malignancies [8]. Atypical carcinoid is even a rarer type of neuroendocrine tumor [3]. They mostly remain asymptomatic until they metastasize at the time of presentation (66% to lymph nodes from pulmonary origin) and behave as aggressive tumors rather than slow growing carcinoids. They are different from carcinoid tumors as they mostly arise in the foregut tissues such as bronchial epithelium and thymus gland. Patients usually have normal levels of serotonin and chromogranin-A in their blood and normal levels of 5-HIAA in their urine; however, they have raised levels of serotonin and 5-hydroxytryptophan (5-HTP) in their urine [1, 3, 9].

There is a case report of atypical carcinoid originating from the thymus gland in the form of a mediastinal mass in association with hypercalcemia which was found to be due to parathyroid adenoma [4]. Another case report of MEN 1 has shown ectopic parathyroid tissue in the mediastinal mass [10] and another has reported thymic carcinoid with atypical course in such patients [11]; however, very limited data are reported on the concomitant presence of parathyroid adenoma and asymptomatic metastatic mediastinal atypical carcinoid other than thymus. A single study has described a clear distinction between such a neuroendocrine tumor originating as ectopic tissue in the mediastinum rather than from a thymus gland [1]. Our patient’s histopathology did not reveal any thymic tissue and has characteristic immunohistochemical staining for the neuroendocrine neoplasms, more specifically for atypical carcinoid tumor. The presence of sheets of cells in the parathyroid tissue (Fig. 3) of our patient presents the metastasis of atypical carcinoid tumor from the mediastinal ectopic neuroendocrine cells, which is a rare entity that has not been described before. Whether this can be the cause of parathyroid adenoma and hyperparathyroidism in our patient and what genetics could be involved is not much known. Besides parathyroid gland, it has also metastasized to lymph nodes, thyroid areas, and peripancreatic areas. Our patient had no clinical stigmata of carcinoid syndrome and has not had any airway obstructive disease (in view of large mediastinal mass). Further evaluation for pituitary tumor in the form of imaging was not possible due to financial limitations; besides, he did not have any clinical features of Cushing’s syndrome or acromegaly. Thus, our patient had multiple endocrine disorders with two neoplasms, of which one was aggressive with a guarded prognosis. Such a clustering can be very well explained as a variant of MEN syndromes and needs genetic analysis, which is not available in our region. Moreover, apart from everolimus therapy, which has been shown to improve prognosis in a trial [12], the octreotide avidity of the metastasis in our patient means that our patient needs octreotide treatment as part of ongoing care, which has limitations in a resource-poor country.

Conclusions

We presented a case of metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma, diagnosed incidentally during preoperative workup. The unusual clustering of neuroendocrine tumors is being increasingly reported in the literature, and patients with hyperparathyroidism should be thoroughly investigated to diagnose and treat other related tumors particularly atypical carcinoid of mediastinum as it has a poor outcome and limited treatment options.

Abbreviations

5-HIAA: 

5-hydroxyindoleacetic acid

5-HTP: 

5-hydroxytryptophan

Tc: 

Technetium-99m

Ca: 

Calcium

eGFR: 

Estimated glomerular filtration rate

HPF: 

High-power field

MEN: 

Multiple endocrine neoplasia

PO4

Phosphate

PTH: 

Parathyroid hormone

SRS: 

Somatostatin receptor scintigraphy

Declarations

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

ZK analyzed and interpreted the patient’s data, performed the literature search, reviewed and edited the manuscript. AA is the primary physician and endocrinologist of the patient; she performed the literature search and was a major contributor in reviewing the manuscript. OR performed the literature search and reviewed the manuscript. SF is the histopathologist of the patient and did the literature search and reviewed the manuscript. FM, SauF and MI did the literature search and reviewed the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate

Ethical approval was waived for this case report.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Section of Endocrinology, Department of Medicine, Aga Khan University Hospital
(2)
Department of Histopathology, Aga Khan University Hospital
(3)
Department of Cardiothoracic Surgery, Aga Khan University Hospital
(4)
Department of Ear, Nose & Throat, Aga Khan University Hospital

References

  1. Moran CA. Primary neuroendocrine carcinomas of the mediastinum: review of current criteria for histopathologic diagnosis and classification. Semin Diagn Pathol. 2005;22(3):223–9.View ArticlePubMedGoogle Scholar
  2. Marx A, Chan J, Coindre J-M, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL. The 2015 WHO classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10(10):1383–95.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Caplin M, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoid. Ann Oncol. 2015;26(8):1604–20.View ArticlePubMedGoogle Scholar
  4. Yamamoto J, Shimanouchi M, Ueda Y, Hashizume T, Suito T. Atypical thymic carcinoid with hypercalcemia. Kyobu geka Japanese J Thorac Surg. 2012;65(13):1150–3.Google Scholar
  5. Lin FC, Lin CM, Hsieh CC, Li WY, Wang LS. Atypical thymic carcinoid and malignant somatostatinoma in type I multiple endocrine neoplasia syndrome: case report. Am J Clin Oncol. 2003;26(3):270–2.PubMedGoogle Scholar
  6. Ahn S, Lee JJ, Ha SY, Sung CO, Kim J, Han J. Clinicopathological analysis of 21 thymic neuroendocrine tumors. Korean J Pathol. 2012;46(3):221–5.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Soga J, Yakuwa Y, Osaka M. Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999;5(5):285–92.PubMedGoogle Scholar
  8. Chaer R, Massad MG, Evans A, Snow NJ, Geha AS. Primary neuroendocrine tumors of the thymus. Ann Thorac Surg. 2002;74(5):1733–40.View ArticlePubMedGoogle Scholar
  9. Kim S-J, Kim JW, Han S-W, Oh D-Y, Lee S-H, Kim D-W, Im S-A, Kim T-Y, Heo DS, Bang Y-J. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer. 2010;10(1):1.View ArticleGoogle Scholar
  10. Takayama T, Kameya T, Inagaki K, Nonaka M, Miyazawa H, Ogawa N, Yano M, Morita T, Arai T, Niino S, et al. MEN type 1 associated with mediastinal carcinoid producing parathyroid hormone, calcitonin and chorionic gonadotropin. Pathol Res Pract. 1993;189(9):1090–6. discussion 1096–1100.View ArticlePubMedGoogle Scholar
  11. Choi YS, Bai YS, Ku BJ, Jo YS, Kim YK, Ro HK, Shong M. A case of multiple endocrine neoplasia type I with atypical clinical course. J Korean Endoc Soc. 2008;23(4):266–71.View ArticleGoogle Scholar
  12. Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, Tajima T, Kasuga A, Fujita Y, Furuse J. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol. 2012;42(10):903–11.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement